The SCALE trials aim to uncover key elements of successful smoking cessation programs by evaluating various intervention combinations.
Dr. Lucia Viola says that access to genomic profiling is crucial for gathering information about patients who do not smoke.
Narjust Florez, MD, and Angela Morabito, BS, launched the #HearHer campaign to raise awareness about the increasing incidence of lung cancer among women and the frequent delays in diagnosis.
A new genetics study aims to collect data from 10,000 participants diagnosed with lung cancer to improve future outcomes and enhance research.
Dr. Mike Gieske said since implementing a multidisciplinary screening approach, his healthcare system has seen a 19% decrease in late-stage lung cancers, and they now see more early-stage than late-stage lung cancers.
Dr. Matt Warkentin says in those without significant comorbidity and who are fit for surgery, screening may provide survival benefits.
Dr. Annette McWilliams says the PanCan nodule management protocol demonstrates potential to streamline lung cancer screening and management processes.
The session will also include late-breaking data from HARMONi-2, NeoCOAST-2, and TROPION-Lung01 as well as an address from IASLC President Dr. Paul Van Schil.
Dr. Caicun Zhou discusses his plans for WCLC 2024 as well as his goals for his time as IASLC President.
Lead author Dr. Claudia Henschke says a recently published perspective from the IASLC Early Detection and Screening Committee explores several components of effective screening efforts, including timing between screenings.